Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy.
Hu Y, Ye Z, Wang F, Qin Y, Xu X, Yu X, Ji S.
Front Endocrinol (Lausanne). 2021 May 19;12:679000. doi: 10.3389/fendo.2021.679000. eCollection 2021.
Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.
Ma ZY, Gong YF, Zhuang HK, Zhou ZX, Huang SZ, Zou YP, Huang BW, Sun ZH, Zhang CZ, Tang YQ, Hou BH.
World J Gastroenterol. 2020 May 21;26(19):2305-2322. doi: 10.3748/wjg.v26.i19.2305.
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators.
N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158.
Surgical techniques and postoperative management to prevent postoperative pancreatic fistula after pancreatic surgery.
Kawaida H, Kono H, Hosomura N, Amemiya H, Itakura J, Fujii H, Ichikawa D.
World J Gastroenterol. 2019 Jul 28;25(28):3722-3737. doi: 10.3748/wjg.v25.i28.3722.
Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia.
Panzuto F, Magi L, Rinzivillo M.
Expert Opin Drug Saf. 2021 Apr;20(4):383-386. doi: 10.1080/14740338.2021.1881478. Epub 2021 Feb 2.
Somatostatin analogues for pancreatic surgery.
Gurusamy KS, Koti R, Fusai G, Davidson BR.
Cochrane Database Syst Rev. 2010 Feb 17;(2):CD008370. doi: 10.1002/14651858.CD008370.
Metastatic pancreatic neuroendocrine tumors have decreased somatostatin expression and increased Akt signaling.
Tran CG, Scott AT, Li G, Sherman SK, Ear PH, Howe JR.
Surgery. 2021 Jan;169(1):155-161. doi: 10.1016/j.surg.2020.04.034. Epub 2020 Jun 29.
The clinical significance of somatostatin in pancreatic diseases.
Sliwińska-Mossoń M, Veselý M, Milnerowicz H.
Ann Endocrinol (Paris). 2014 Sep;75(4):232-40. doi: 10.1016/j.ando.2014.06.004. Epub 2014 Aug 22.
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is 10%?
Merola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pellè E, Kolasińska-Ćwikła A, Zandee W, Laskaratos F, de Mestier L, Lamarca A, Hernando J, Cwikla J, Strosberg J, de Herder W, Caplin M, Cives M, van Leeuwaarde R.
Oncologist. 2021 Apr;26(4):294-301. doi: 10.1002/onco.13633. Epub 2020 Dec 29.
Somatostatin receptor SPECT.
Pepe G, Moncayo R, Bombardieri E, Chiti A.
Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S41-51. doi: 10.1007/s00259-011-2019-2.
